Pairing up to advance CAR T cell therapies: a dual-targeting approach to solid tumours

Mar 23, 2026

A partnership between Link Cell Therapies and CTMC is advancing next-generation CAR T therapies for solid tumours by combining dual-targeting “logic-gated” engineering with integrated manufacturing and clinical development to improve precision, safety and speed to trials

Read the full article here: https://manufacturingchemist.com/pairing-up-to-advance-car-t-cell-therapies

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez – Part 2

May 7, 2026

When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from...

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez – Part 1

May 5, 2026

The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the...

Base to Base biotech podcast #55: The circular supply chain

Apr 17, 2026

CTMC is a joint venture between Resilience and the MD Anderson Cancer Center. It works like an internal manufacturing group, adapting to change...

Back

Pairing up to advance CAR T cell therapies: a dual-targeting approach to solid tumours

Recent News

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez – Part 2

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez – Part 1

Base to Base biotech podcast #55: The circular supply chain

Explore CTMC

Resources + Support

Contact Us